Skip to main content

Table 1 Characteristics of trials included in the analysis

From: Effectiveness of Menthacarin on symptoms of irritable bowel syndromeWirksamkeit von Menthacarin bei Symptomen des Reizdarmsyndroms

  Trial A Trial B Trial C
Publication May et al. [17] Freise and Köhler [13] Madisch et al. [15]
Treatment 3 × 1 enteric-coated capsule/day Menthacarin (total daily dose of 270 mg peppermint oil and 150 mg caraway oil) or placebo for 4 weeks 3 × 1 enteric-coated capsule/day Menthacarin (total daily dose of 270 mg peppermint oil and 150 mg caraway oil) or enteric-soluble comparator for 4 weeks (total daily dose of 108 mg peppermint oil and 60 mg caraway oil) 2 × 1 enteric-coated capsule/day Menthacarin (total daily dose of 180 mg peppermint oil and 100 mg caraway oil) or 3 × 10 mg cisapride for 4 weeks
Patients with IBS/total (ITT) Menthacarin: 12/22 (55%) Menthacarin: 40/108 (37%) Menthacarin: 5/60 (8%)
Placebo: 10a/23 (44%) Comparator: 42/105 (40%) Comparator: 3/58 (5%)
Primary selection criteria Adult outpatients suffering from FD, with or without concomitant IBS symptoms; presence of at least two dyspeptic and/or bowel associated symptoms for at least 14 days; absence of an organic cause of symptoms; informed consent prior to study participation
Primary outcome measure Change in intensity of pain Change in intensity of pain Change in intensity of pain
CGI Item 2
Secondary outcome measures with relevance to IBS Flatulence; feelings of pressure/heaviness/fullness; diarrhea Flatulence; feelings of pressure/heaviness/fullness; diarrhea Flatulence; feelings of pressure/heaviness/fullness; diarrhea
CGI items 1 + 3 CGI items 1–3 CGI items 1–3
  1. Menthacarin® is the active ingredient of the product Carmenthin® (Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany)
  2. IBS irritable bowel syndrome, FD functional dyspepsia, ITT intention-to-treat, CGI clinical global impressions scale
  3. aOne patient out of 10 was not evaluable because of missing data under therapy